Faculty Information - Masahiro Yamamura

（Last updated : 2023-06-05 14:44:11）

Masahiro Yamamura
Department Kawasaki Medical School Faculty of Medicine, Kawasaki Medical School,

Position

■ Journal

1.	2022/09/29	Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay
2.	2022/02	Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate- Activated Killer (ZAK) Cells – An Analysis for Patients With Incurable Pancreatic Cancer
3.	2022	Advanced gastrointestinal stromal tumor with intracerebral hemorrhage during sunitinib treatment
4.	2022	Severe thrombocytopenia and maculopapular erythema-induced by regorafenib in a patient with advanced gastrointestinal stromal tumor
5.	2022	Sorafenib-induced apoptosis in colonic neuroendocrine carcinoma cells
6.	2021/12/22	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors
7.	2020/10/24	Nanoparticle-mediated delivery of 2-deoxy-D-glucose induces antitumor immunity and cytotoxicity in liver tumors in mice.
8.	2020/08/24	Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study
9.	2020/04	Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
10.	2019/08	Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts.
11.	2019/03	DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
12.	2018/11	Extracellular S100A11 plays a critical role in spread of the fibroblast population in pancreatic cancers
13.	2018/01	DKK3 Overexpression Increases Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
14.	2017/03	Evaluation of pancreatic cancer cell migration with multiple parameters in vitro by using an optical real-time cell mobility assay device
15.	2015/09	Current Cancer Immunotherapy Using Activated Lymphocytes -Do Lymphocytes Actually Recognize Cancer Cells?
16.	2015/02	Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors
17.	2014/11	Imatinib Plasma Levels during Successful Long-Term Treatment of Metastatic Gastrointestinal Stromal Tumors
18.	2014/10	Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature
19.	2014/06	Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer
20.	2014/04	Metformin suppresses sonic hedgehog expression in pancreatic cancer cells
21.	2013/10	Eicosapentaenoic Acid Modifies Cytokine Activity and Inhibits Cell Proliferation in an Oesophageal Cancer Cell Line
22.	2011/11	Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors
23.	2006/12	Induction of Dihydropyrimidine Dehydrogenase Expression by Mitomycin C in Colorectal Cancer
24.	2006	Lower esophageal sphincter- and vagus-preserving proximal partial gastrectomy for early cancer of the gastric cardia.
25.	2005/10	In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
26.	2005/02	Surgical oncotaxis--excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients.
Display 5 items
Display all(26)

■ Presentation

1.	2023/03/15	Pre-treatment PD-1 lymphocyte ratio in blood may predict clinical outcome of gastric cancer patients under Nivolumab monotherapy （Speech，General）
2.	2022/02/17	Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy （Poster notice，General）
3.	2020/10/01	DKK3 regulates malignant property of head and neck squamous cell carcinoma via phosphorylation of Akt. （Poster notice，General）
4.	2020/10/01	Eextracellular S100A11 upregulates mobility of pancreatic cancer cells through activation of surrounding fibroblasts. （Poster notice，General）
5.	2020/10/01	HSP90 inhibition suppresses not only cell proliferation but also chemotaxis in esophageal squamous cell carcinoma （Speech，General）
6.	2020/10/01	NOX4 on lymphatic endothelial cells (LEC) plays an important role on the migration of pancreatic cancer cells towards lymphatics. （Speech，General）
7.	2019/07/05	Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors （Poster notice，General）
8.	2019/04/01	Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells （Poster notice，General）
9.	2018/11/24	Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer. （Poster notice，General）
10.	2018/11/10	Clinico-pathological features of hypermutant colorectal cancers analyzed over 1000 colorectal cancer （Speech，Panelist at Symposium/Workshop (Other)）
11.	2018/10/22	Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors （Poster notice，General）
12.	2018/10/21	Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients （Poster notice，General）
13.	2018/09/27	Migration of Pancreatic Cancer cell BxPC-3 is suppressed by ROS （Speech，General）
14.	2017/04/27	Knockdown of DKK3 gene reduces malignant properties of oral squamous cell carcinoma-derived cells （Poster notice，General）
15.	2017/04/03	Heat shock protein 90 inhibitors suppress PDGFRA reactivation and other receptor tyrosine kinase activation important in drug resistant gastrointestinal stromal tumors. （Poster notice，General）
16.	2016/10/06	Exploring serum factors for evoking and promoting cancer metastasis （Poster notice，General）
17.	2016/10/06	HSP90 inhibitor inhibit the activation of proliferation, chemotaxis and EMT in pancreatic cancer cells （Speech，General）
18.	2016/05/18	HSP90 inhibitor inhibit the activation of multiple kinase pathways and migration of pancreatic cancer cells. （Poster notice，General）
19.	2015/12/20	Imatinib plasma levels and clinical features of successful long-term treatment of metastatic gastrointestinal stromal tumors （Poster notice，General）
20.	2015/12/20	Successful treatment of everolimus for a renal impairment patient with neuroendocrine tumor （Poster notice，General）
21.	2015/10/10	Functional analyses of DKK3 in oral squamous cell carcinoma cell lines （Poster notice，General）
22.	2015/10/09	HSP90 inhibitor inhibit the activation of multiple kinase pathways of pancreatic cancer cells （Speech，General）
23.	2015/07/10	Suppressing pancreatic cancer metastasis by small molecular compunds （Poster notice，General）
24.	2015/04/20	The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma （Poster notice，General）
25.	2014/11/25	Basic research for inhibiting pancreatic cancer metastasis: Gemcitabine vs Dasatinib （Poster notice，General）
26.	2014/11/13	Effect of HSP90 inhibitor on proliferation and migration in esophageal squamous cell carcinoma （Speech，General）
27.	2014/09/25	Antitumor effect of HSP90 inhibitor against esophageal cancer （Poster notice，General）
28.	2014/07/17	Clinicopathological study of gastrointestinal neuroendocrine tumor. （Poster notice，General）
29.	2013/02/25	Possibility of combination therapy of molecular targeted drugs for gastrointestinal stromal tumor. （Poster notice，General）
30.	2012/09/20	Antitumor effect of Hsp90 inhibitor in neuroendocrine tumor （Poster notice，General）
31.	2011/07/01	Wnt signaling during transition from cell proliferation to differentiation in myoblast cells. （Poster notice，General）
32.	2011/07/01	Wnt signaling involved in gastrointestinal neuroendocrine tumors. （Poster notice，General）
33.	2010/09/04	Cancer vaccine in combination with Anti-CD25 antibody for advanced esophageal squamous cell carcinoma. –a case of the prolonged stable disease （Poster notice）
34.	2010/08/25	A case with postoperative bone metastasis of gastrointestinal stromal tumor (GIST) expressing exon 8 mutation of KIT （Poster notice）
35.	2010/08/25	Cancer Vaccine in Combination with Anti-CD25 Antibody for Advanced Esophageal Squamous Cell Carcinomas –A Case of the Prolonged Stable Disease- （Poster notice）
36.	2008/03/24	Antitumor effect and signaling mechanism of tranilast in gastric cancer cell lines. （Poster notice，General）
37.	2008/03/24	Interaction of Wnt4 with myostatin signaling during myogenic differentiation of skeletal muscle. （Poster notice，General）
38.	2007/06/21	Different beta-catenin immunoexpression in gastrointestinal neuroendcrine tumors (carcinoid tumors). （Poster notice，General）
39.	2007/06/21	Nuclear expression of beta-catenin in oral leukoplakia with or without dysplasia （Poster notice，General）
40.	2006/02/22	A pilot study of combined chemotherapy with docetaxel and nedaplatin as a second line for unresectable or recurrent esophageal carcinoma
41.	2006/02/22	Excessive surgical stress of thoraco-laparotomy contributes to enhancing tumor metastasis and poor prognosis(surgical or stress oncotaxis) （Poster notice）
42.	2006/02/22	How to control cytokine storm after thoraco-laparotomy, experimentally and clinically
43.	2005/05/05	Technique and results of LES/vagus nerve-preserving proximal partial gastrectomy for cardia cancer
44.	2004/06/05	Determination of a second-line chemotherapy agent for patients with colorectal cancer (CRC) after fluorouracil failure （General）
45.	2004/06/02	Duplication of common bile duct: A review of the literature （General）
46.	2004/06/02	Inflammatory pseudotumor of the spleen: report of three cases （General）
47.	2003/05/31	Cender differences in the dihydropyrimidine dehydrogenase(DPD) expression and 5-fluorouracil (5-FU) sensitivity of colorectal cancers (CRCs).
Display 5 items
Display all(47)

■ Belonging society

1.		Japan Surgical Society
2.		The Japanese Gastroenterological Association
3.		Japan Society of Clinical Oncology
4.		Japanese Cancer Association